The best thing that happens to us is when a great company gets into temporary trouble ... We want to buy them when they're on the operating table. - Warren Buffett
As the weekend is winding down, I'll conduct competitive intelligence analysis on Amarin Corporation (AMRN). The inspiration from a ScienceDirect article that an Integrated BioSci Investing ("IBI") member shared catalyzed this analysis. As such, I'd like to express my gratitude to all IBI members for your continuous intellectual generosity. Equally important, I appreciate the counter-viewpoint. And, I encourage you to continue sharing your inputs.
In my view, IBI is a community where we learn from one another to become better investors. Therefore, all respectful debates are welcoming. By dissecting opposing arguments, we can learn about an investing thesis on a deeper level where most value resides. Without further ado, I'll take a deep-dive into this commentary.
Figure 1: Amarin chart (Source: StockCharts)
Accordingly, I found the recent article on Vascepa's competitor intriguing for various reasons. Notwithstanding, they all underlies the "impurity" and "subpar quality" of over-the-counter supplements (i.e. OOS), which I attributed to their regulatory laxity. The author remarked,
Elucida Research in Beverly, MA, found that Omega-3 fatty acid (3FA) levels fluctuated greatly from product to product, from as low as 33% to as high as 79%. However, it also determined that high levels of saturated fat and oxidized 3FA found in the supplements may actually undermine their possible health benefits.
As Elucida elucidated, one can best hope for a 79% Omega-3 from OOS. Adding further injury to insult, I believe that the aforementioned 79% is not pure eicosapentaenoic acid (EPA) like Vascepa. Asides from "fillers and oxidized Omega-3," OOS harbors the silent cardiovascular-disease inciter (i.e. docosahexaenoic acid or DHA).
... You can access read the rest of this FREE article by clicking HERE.
Thanks for reading! Please hit the orange "Follow" button on top for updates.
Dr. Tran's analyses are the best in the biotech sphere, well worth the price of subscription.
Very professional, extremely knowledgeable, and very honest … I would highly recommend this service and his stock picks have been very profitable.
Simply put, this is worth every penny. Just earlier today, one of the companies recommended by Dr. Tran got acquired for a nice 50% premium.
As I reserve higher market intelligence and exclusive features for IBI members, I invite you to take my temporary offer of 2 weeks FREE TRIAL.
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
Additional disclosure: As a medical doctor/market expert, Dr. Tran is not a registered investment advisor. Despite that we strive to provide the most accurate information, we neither guarantee the accuracy nor timeliness. Past performance does NOT guarantee future results. We reserve the right to make any investment decision for ourselves and our affiliates pertaining to any security without notification except where it is required by law. We are also NOT responsible for the actions of our affiliates. The thesis that we presented may change anytime due to the changing nature of information itself. Investment in stocks and options can result in a loss of capital. The information presented should NOT be construed as recommendations to buy or sell any form of security. Our articles are best utilized as educational and informational materials to assist investors in your own due diligence process. That said, you are expected to perform your own due diligence and take responsibility for your actions. You should also consult with your own financial advisor for specific guidance, as financial circumstances are individualized.